Telix Pharmaceuticals Limited (ASX:TLX)
Australia
· Delayed Price · Currency is AUD | Market Cap | 5.02B |
| Revenue (ttm) | 1.01B |
| Net Income (ttm) | 16.54M |
| Shares Out | 338.70M |
| EPS (ttm) | 0.07 |
| PE Ratio | 227.71 |
| Forward PE | 219.08 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 896,050 |
| Average Volume | 1,378,315 |
| Open | 14.76 |
| Previous Close | 14.56 |
| Day's Range | 14.62 - 14.98 |
| 52-Week Range | 13.30 - 31.97 |
| Beta | 1.22 |
| RSI | 48.83 |
| Earnings Date | Jan 15, 2026 |
About Telix Pharmaceuticals
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ... [Read more]
Financial Performance
In 2024, Telix Pharmaceuticals's revenue was $484.69 million, an increase of 41.49% compared to the previous year's $342.57 million. Earnings were $30.89 million, an increase of 769.68%.
Financial numbers in USD Financial StatementsNews
TLX LAWSUIT DEADLINE: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain
Partner Reed Kathrein Scrutinizes Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) SAN FRANCISCO , Dec. 5, 2025 /PRNewswire/ -- Natio...
TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, Dec. 05, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Telix Pharmaceuticals Limited (“...
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 9, 2026 in Telix Pharmaceuticals Ltd. Lawsuit – TLX
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action secur...
TLX LAWSUIT DEADLINE: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain
Partner Reed Kathrein Scrutinizes Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) Partner Reed Kathrein Scrutinizes Alleged Misstate...
TLX Class Action Reminder: Telix Pharmaceuticals Ltd. Stockholders Should Contact Robbins LLP for Information About Leading the Class Action Against TLX
TLX Class Action Reminder: Telix Pharmaceuticals Ltd. Stockholders Should Contact Robbins LLP for Information About Leading the Class Action Against TLX
Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds purchasers or acquirers of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) (“Telix”) American Depositary Shares (...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options
The Gross Law Firm Reminds Telix Pharmaceuticals Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 - TLX
NEW YORK , Dec. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX).
Telix Pharmaceuticals Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – TLX
LOS ANGELES, Dec. 04, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) for violatio...
ROSEN, LEADING INVESTOR COUNSEL, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLX
New York, New York--(Newsfile Corp. - December 3, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between F...
TLX LAWSUIT DEADLINE: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain
Partner Reed Kathrein Scrutinizes Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) SAN FRANCISCO , Dec. 3, 2025 /PRNewswire/ -- Natio...
The Gross Law Firm Notifies Shareholders of Telix Pharmaceuticals Ltd. (TLX) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX).
Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
BENSALEM, Pa. , Dec. 3, 2025 /PRNewswire/ -- The Law Offices of Howard G.
ROSEN, NATIONAL TRIAL ATTORNEYS, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLX
New York, New York--(Newsfile Corp. - December 2, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between F...
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Telix to Contact Him Directly to Discuss Their Options If you purchased or acquired s...
Telix Pharmaceuticals (TLX) Sued After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability – Hagens Berman
SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Ltd. (NASDAQ: TLX), a commercial-stage biopharmaceutical company specializing in diagnostic and therapeutic radiopharmaceuticals,...
ATTENTION NASDAQ: TLX INVESTORS: Contact Berger Montague About a Telix Pharmaceuticals Ltd. Class Action Lawsuit
PHILADELPHIA , Dec. 2, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Te...
Levi & Korsinsky Reminds Telix Pharmaceuticals Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 - TLX
NEW YORK , Dec. 2, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd.
TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Ltd. Securities Fraud Lawsuit Filed by The Rosen Law Firm
NEW YORK , Dec. 1, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 a...
Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately
Lead Plaintiff Deadline is January 9, 2026 NEW YORK , Dec. 1, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP reminds purchasers or acquirers of Telix Pharmaceuticals Ltd. (NASDAQ: TLX)...
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options If you purchased or acquired s...
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – TLX
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 20...
Telix Pharmaceuticals (TLX) Faces Securities Class Action After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman
SAN FRANCISCO , Dec. 1, 2025 /PRNewswire/ -- Telix Pharmaceuticals Ltd. (NASDAQ: TLX), a commercial-stage biopharmaceutical company specializing in diagnostic and therapeutic radiopharmaceuticals, is ...
TLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Telix Pharmaceuticals Limited Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed ag...
Investors in Telix Pharmaceuticals Ltd. Should Contact The Gross Law Firm Before January 9, 2026 to Discuss Your Rights - TLX
NEW YORK , Dec. 1, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX).